Virpax Pharmaceuticals, Inc.

0.30 USD
-0.01 (-3.56%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Virpax Pharmaceuticals, Inc. stock is down -9.38% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 February’s closed higher than January.

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. develops various drug-delivery systems and drug-releasing technologies. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee. AnQlar, an anti-viral barrier to prevent or reduce the risk of viral infections in humans, including influenza and SARS-CoV-2.